OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
Susan Slovin
Frontiers in Oncology (2012) Vol. 2
Open Access | Times Cited: 10
Susan Slovin
Frontiers in Oncology (2012) Vol. 2
Open Access | Times Cited: 10
Showing 10 citing articles:
Dendritic cells and cancer immunotherapy
Kristen J. Radford, Kirsteen M. Tullett, Mireille H. Lahoud
Current Opinion in Immunology (2014) Vol. 27, pp. 26-32
Closed Access | Times Cited: 115
Kristen J. Radford, Kirsteen M. Tullett, Mireille H. Lahoud
Current Opinion in Immunology (2014) Vol. 27, pp. 26-32
Closed Access | Times Cited: 115
Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana‐Farber Cancer Institute, 2011 to 2019
Yuanming Xu, Natalie Wen, Stephen T. Sonis, et al.
Cancer (2021) Vol. 127, Iss. 11, pp. 1796-1804
Open Access | Times Cited: 38
Yuanming Xu, Natalie Wen, Stephen T. Sonis, et al.
Cancer (2021) Vol. 127, Iss. 11, pp. 1796-1804
Open Access | Times Cited: 38
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy
Charles G. Drake, Padmanee Sharma, Winald R. Gerritsen
Oncogene (2013) Vol. 33, Iss. 43, pp. 5053-5064
Open Access | Times Cited: 47
Charles G. Drake, Padmanee Sharma, Winald R. Gerritsen
Oncogene (2013) Vol. 33, Iss. 43, pp. 5053-5064
Open Access | Times Cited: 47
High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma
Roya Ghods, Mohammad‐Hossein Ghahremani, Zahra Madjd, et al.
Cancer Immunology Immunotherapy (2014) Vol. 63, Iss. 12, pp. 1319-1327
Open Access | Times Cited: 42
Roya Ghods, Mohammad‐Hossein Ghahremani, Zahra Madjd, et al.
Cancer Immunology Immunotherapy (2014) Vol. 63, Iss. 12, pp. 1319-1327
Open Access | Times Cited: 42
Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies
Wanxiao Sun, Yaxin Deng, Meihui Zhao, et al.
Journal of Controlled Release (2021) Vol. 333, pp. 41-64
Closed Access | Times Cited: 28
Wanxiao Sun, Yaxin Deng, Meihui Zhao, et al.
Journal of Controlled Release (2021) Vol. 333, pp. 41-64
Closed Access | Times Cited: 28
Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome
Carolina Tiraboschi, Lucas D. Gentilini, Carla Velazquez, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001535-e001535
Open Access | Times Cited: 15
Carolina Tiraboschi, Lucas D. Gentilini, Carla Velazquez, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001535-e001535
Open Access | Times Cited: 15
Prostate cancer vaccines in combination with additional treatment modalities
Matthew A. Uhlman, Megan T. Bing, David M. Lubaroff
Immunologic Research (2014) Vol. 59, Iss. 1-3, pp. 236-242
Closed Access | Times Cited: 15
Matthew A. Uhlman, Megan T. Bing, David M. Lubaroff
Immunologic Research (2014) Vol. 59, Iss. 1-3, pp. 236-242
Closed Access | Times Cited: 15
Castration-resistant prostate cancer: potential targets and therapies
Neehar Bhatia, Hifzur R. Siddique, Badrinath R. Konety, et al.
Biologics (2012), pp. 267-267
Open Access | Times Cited: 14
Neehar Bhatia, Hifzur R. Siddique, Badrinath R. Konety, et al.
Biologics (2012), pp. 267-267
Open Access | Times Cited: 14
Quo Vadis Advanced Prostate Cancer Therapy? Novel Treatment Perspectives and Possible Future Directions
Jana Kvízová, Vladimíra Svobodová Pavlíčková, Eva Kmonı́čková, et al.
Molecules (2021) Vol. 26, Iss. 8, pp. 2228-2228
Open Access | Times Cited: 6
Jana Kvízová, Vladimíra Svobodová Pavlíčková, Eva Kmonı́čková, et al.
Molecules (2021) Vol. 26, Iss. 8, pp. 2228-2228
Open Access | Times Cited: 6
Galectin-3 as a new negative checkpoint of the immune response is the key target for effective immunotherapy against prostate cancer
Carolina Tiraboschi, Lucas D. Gentilini, Felipe M. Jaworski, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2019)
Open Access | Times Cited: 4
Carolina Tiraboschi, Lucas D. Gentilini, Felipe M. Jaworski, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2019)
Open Access | Times Cited: 4
